CG
PDLI

Cutler Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Cutler Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,910
Closed -$27K – 7715
2017
Q1 		$27K Hold
11,910
– – ﹤0.01% 3054
2016
Q4 		$25K Hold
11,910
– – ﹤0.01% 3256
2016
Q3 		$39K Hold
11,910
– – ﹤0.01% 2718
2016
Q2 		$37K Hold
11,910
– – ﹤0.01% 2695
2016
Q1 		$39K Buy
11,910
+5,000
+72% +$15.6K ﹤0.01% 2601
2015
Q4 		$24K Buy
+6,910
New +$28.9K ﹤0.01% 3250

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Cutler Group's PDLI Position: Q2 2017 in Review

Cutler Group sold out of PDL BioPharma, Inc. (PDLI) in Q2 2017, closing a stake of 11,910 shares — an estimated $27K sold.

Cutler Group first reported a position in PDLI in Q4 2015 and held it in 6 quarters. The position peaked at $39K in Q3 2016. 171 funds tracked by Wall St. Rank hold PDLI as of Q2 2017.

  • Cutler Group reported no remaining PDL BioPharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Cutler Group sold 11,910 PDL BioPharma, Inc. shares in Q2 2017, an estimated $27K.
  • Cutler Group first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 6 quarters.
  • Cutler Group's PDL BioPharma, Inc. position peaked at $39K in Q3 2016.
  • 171 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.